Clinical significance of the LacdiNAc‐glycosylated prostate‐specific antigen assay for prostate cancer detection

To reduce unnecessary prostate biopsies (Pbx), better discrimination is needed. To identify clinically significant prostate cancer (CSPC) we determined the performance of LacdiNAc‐glycosylated prostate‐specific antigen (LDN‐PSA) and LDN‐PSA normalized by prostate volume (LDN‐PSAD). We retrospectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneyama, Tohru, Tobisawa, Yuki, Kaneko, Tomonori, Kaya, Takatoshi, Hatakeyama, Shingo, Mori, Kazuyuki, Sutoh Yoneyama, Mihoko, Okubo, Teppei, Mitsuzuka, Koji, Duivenvoorden, Wilhelmina, Pinthus, Jehonathan H., Hashimoto, Yasuhiro, Ito, Akihiro, Koie, Takuya, Suda, Yoshihiko, Gardiner, Robert A., Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676104/
https://www.ncbi.nlm.nih.gov/pubmed/31145522
http://dx.doi.org/10.1111/cas.14082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676104/
https://www.ncbi.nlm.nih.gov/pubmed/31145522
http://dx.doi.org/10.1111/cas.14082

Ejemplares similares